Biopharmaceuticals KYTH today announced it has commenced an
underwritten public offering of shares of its common stock to raise
aggregate proceeds of $100 million. All of the shares of the common stock to
be sold in the offering will be offered by KYTHERA.
KYTHERA intends to use the net proceeds of the offering to fund the ongoing
development and preparation for potential commercialization of ATX-101,
including the preparation and submission of its New Drug Application, or
NDA, for ATX-101, and the balance for working capital and general corporate
purposes, including research and development.
J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint
book-running managers, and representatives of the underwriters for the
offering. Leerink Swann LLC is also acting as a joint book-running manager.
Cowen and Company, LLC is acting as co-manager. KYTHERA intends to grant the
underwriters a 30-day option to purchase up to an additional 15 percent of
the number of shares sold to cover over-allotments, if any. The offering is
subject to market conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of the
offering.
The offering will be made only by means of a prospectus. Copies of the
prospectus relating to the offering may be obtained from: J.P. Morgan
Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by calling toll-free (866) 803-9204; or from the
offices of BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, or via email, at dg.prospectus_requests@baml.com
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of novel
prescription products for the aesthetic medicine market. KYTHERA's product
candidate, ATX-101, is currently in late stage clinical trials for the
reduction of submental fat, which commonly presents as a double chin, and is
a potential first-in-class submental contouring injectable drug. KYTHERA
also maintains an active research interest in hair and fat biology,
pigmentation modulation and facial contouring. Find more information at
http://www.kytherabiopharma.com.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding KYTHERA, they are forward-looking
statements reflecting the current beliefs and expectations of management
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve
substantial risks and uncertainties that could cause our actual results,
performance or achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and uncertainties
include, among others, the timing and size of the offering, the conditions
affecting the capital markets, general economic, industry, or political
conditions, and the satisfaction of customary closing conditions related to
the proposed public offering. KYTHERA undertakes no obligation to update or
revise any forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks relating to
the business of the company in general, see the prospectus for this offering
included as part of the Registration Statement on Form S-1/A filed by
KYTHERA on October 7, 2013, as well as KYTHERA 's Annual Report on Form 10-K
for the year ended December 31, 2012 and its other reports filed with the
Securities and Exchange Commission.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in